演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

切除不能進行・再発大腸癌に対するFOLFOXIRI+bevacizumab療法の有効性と安全性の検討

演題番号 : P18-3

[筆頭演者]
演者)青松 直撥:1 
[共同演者]
内間 恭武:1、宮本 裕成:1、岡田 拓真:1、辻尾 元:1、栗原 重明:1、平川 俊基:1、岩内 武彦:1、森本 純也:1、山片 重人:1、中澤 一憲:1、竹内 一浩:1

1:生長会府中病院・外科センター

 

Background:
The TRIBE study confirmed FOLFOXIRI plus bevacizumab as a standard initial therapy for metastatic colorectal cancer. However, frequent severe adverse events such as febrile neutropenia were reported in Japanese patients. We reported the safety and efficacy of FOLFOXIRI plus bevacizumab for Metastatic colorectal cancer in our hospital, retrospectively.
Method:
A total of 6 patients (Mele:Female=5:1,median age 63.5 (59-68), ECOG PS 0) were enrolled in this study at our hospital. They were treated by FOLFOXIRI plus bevacizumab (TRIBE regimen; 165 mg/m2 of irinotecan, 3,200 mg/m2 of infusional 5-FU ). On day 4, G-CSF administered as primary prevention in patients with possible neutropenia and febrile neutropenia. Japanese herbal medicine was taken in combination.
Reslts:
As for the UGT1A1 genotypes, 4 patients had a wild-type allele, and 2 patients had a single-heterozygous allele of *6. Site of primary tumor were sigmoid colon 1, rectum 4, multiple 1. Up to 6 cycles of treatment were administered, followed by FOLFIRI plus bevacizumab 6cycles, followed by fluorouracil plus bevacizumab until disease progression. In induction therapy, all patients completed all cycles of induction therapy. Dose reduction of induction therapy was nothing. Complete response was achieved in 1 patient, after 4 cycles of FOLFOXIRI plus bevacizumab, peritoneal dissemination resection was performed. Objective response rate (ORR) was 100%. 3 patients received maintenance therapy and the median number of cycles per patient was 20, ranging from 1 to 22. The adverse events of grade 3 or 4 were nothing. Grade 2 toxicities were diarrhea (33%), and epistaxis (16%). Peripheral neuropathy, Neutropenia and febrile neutropenia were nothing.
Conclusion:
FOLFOXIRI plus bevacizumab is a very effective first-line regimen for metastatic colorectal cancer. Treatment with FOLFOXIRI plus bevacizumab is manageable by adopting appropriate measures (such as G-CSF, Japanese herbal medicine).

キーワード

臓器別:大腸・小腸

手法別:化学療法

前へ戻る